Journal
ANTIVIRAL RESEARCH
Volume 128, Issue -, Pages 43-48Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2016.02.006
Keywords
HCV; Statins; CLDN-1; LDLR; NPC1L1; CD81; PCSK9; Lipids; Cholesterol
Categories
Funding
- CIHR Grant [MOP 93792]
- Canada Research Chair [216684]
Ask authors/readers for more resources
Statins are used daily by a large and increasing number of individuals worldwide. They were initially designed as 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) inhibitors to treat patients with hypercholesterolemia. Recent studies on HCV chronically infected individuals have suggested that their use in vivo in combination with PEG-IFN and ribavirin favor the sustained viral response (SVR). Herein, we describe the effects of a set of statins on HCV entry and on HCV key entry factors in vitro. Our results suggest that all tested statins exert a proviral effect through the upregulation of LDLR. Interestingly, at higher concentration, we also provide evidence of a yet unknown competing antiviral effect of statins (except for pravastatin) through the downregulation of CLDN-1. Importantly, this work enlightens the blunt proviral effect of pravastatin at the entry step of HCV in vitro. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available